SSA
IMNM icon

Schonfeld Strategic Advisors’s Immunome IMNM Stock Holding History

Schonfeld Strategic Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.8M Buy
132,091
+69,655
+112% +$1.49M 0.01% 894
2026
Q1 		$1.37M Buy
62,436
+30,337
+95% +$675K 0.01% 963
2025
Q4 		$689K Sell
32,099
-40,959
-56% -$719K ﹤0.01% 1268
2025
Q3 		$856K Buy
+73,058
New +$727K ﹤0.01% 1458
2023
Q4 		– Sell
-18,201
Closed -$152K – 2032
2023
Q3 		$152K Buy
+18,201
New +$134K ﹤0.01% 1457

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Schonfeld Strategic Advisors's IMNM Position: Q2 2026 in Review

Schonfeld Strategic Advisors increased its Immunome (IMNM) stake by 112% in Q2 2026, buying an estimated $1.49M and bringing the position to 132,091 shares worth $2.8M. The position accounts for 0.01% of the portfolio, ranked #894.

Schonfeld Strategic Advisors first reported a position in IMNM in Q3 2023 and has held it in 5 quarters since. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Schonfeld Strategic Advisors held 132,091 shares of Immunome worth $2.8M as of Q2 2026.
  • Schonfeld Strategic Advisors bought 69,655 Immunome shares in Q2 2026, an estimated $1.49M.
  • Immunome made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #894 holding.
  • Schonfeld Strategic Advisors first reported a position in Immunome in Q3 2023 and has held it in 5 quarters since.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.